1[1]Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst,1991,83(12)∶855-861.
2[2]Roth BJ,Johnson DH, Einhorn LH,et al.Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer:a phase Ⅲ trial of the Southeastern Cancer Study Group.J Clin Oncol,1992,10(2)∶282.
3[3]Feld R, Evans WK, Coy P, et al. Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. J Clin Oncol,1996,5(9)∶1401-1409.
4[4]Postmus PE, Scagliotti G, Groen HJ, et al. Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC Phase Ⅲ trial. Eur J Cancer,1996,32A(9)∶1498-1503.
5[5]Giaccone G, Dalesio O, McVie GJ, et al. Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Can-cer Cooperative Group. J Clin Oncol,1993,11(7)∶1230-1240.
6[6]Bleehen NM, Fayers PM, Girling DJ, et al. Controlled trial of twelve versus six courses of chemotherapy in the treatment of small cell lung cancer. Br J cancer,1994,59(2)∶584.
7[7]Bleehen NM, Girling DJ, Machin D, et al. A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). Ⅱ: quality of life. Medical Research Council Lung Cancer Working Party. Br J Cancer,1993,68(6)∶1157-1166.
8[8]Ihde DC, Mulshine JL, Kramer BS, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol,1994,12(10)∶2022-2034.
9[9]Arriagada R, Le Chevalier T, Pignon JP, et al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med,1993,329(25)∶1848-1852.
10[10]Groen HJ, Fokkema E, Biesma B, et al. Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule. J Clin Oncol,1999,17(3)∶927-932.
6Fukuda M,Soda H,Soejima Y,et al.A phase I trial of carboplatin and etoposide for elderly (>or=75 year-old) patients with small-cell lung cancer [ J ].Cancer Chemother Pharmacol,2006,58(5):601 606.
7汤钊猷 朱世能 曹世龙 等.现代肿瘤学[M].上海：上海医科大学出版社,1997.1075.
8Mavroudis D,Veslemes M,Kourousis Ch,et al.Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC)[J].A multicenter phase Ⅱ study Lung cancer,2002,38 (1):59-63.
